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Abstract
This review article combines four disparate observations about Neural Tube Defects (NTDs). They
are the worldwide decline in the birth incidence that began prior to prenatal diagnosis; family
recurrence risks; the effect of prenatal diagnosis and termination of affected pregnancies; and the
effect of folic acid.
Discussion
Variations in birth incidence
NTDs are due to many different causes [1]. The incidence
varies and some etiologies are more common at different
prenatal ages and birth [2-5]. Epidemiological data from
the period before in-utero diagnosis and termination of
affected pregnancies established two trends. The first illus-
trated epidemics of the incidence of NTDs that cycled over
years, and the second established that there has been a
general decline in the birth incidence of NTDs over several
decades, which has been noted worldwide. The best exam-
ple of epidemics of the occurrence of NTDs was reported
from Birmingham, England [6]. The prevalence rose from
2.0 per 1000 births in 1936–7, to 2.8 in 1940, fell to 1.54
in 1948 and peaked again in 1956 at 2.8 per 1000.
Elwood and Elwood [7] have documented both "epidem-
ics" and the decline in incidence worldwide. Other "epi-
demics" have been described in Boston, Providence and
New York in the USA, Canada, Berlin and in Western Ger-
many, and in a number of other areas [7]. The general
decline in birth incidence has been reported in most
countries studied but it has occurred at different times. A
variation within countries was also reported, with a
Northeast to Southwest gradient from higher to lower in
the UK and from East to West in Canada and the USA. For
example, the highest occurrence risk for the general popu-
lation on the North American continent is 2.5 – 3.5 per
1000 amongst citizens of Nova Scotia [8]. These data
include findings of elective terminations, spontaneous
miscarriages and births. The lowest general population
occurrence is 0.21 – 0.03 per 1000 live births in the Pacific
Northwest of the USA (Figure 1). These geographic varia-
tions may relate to migrations of ethnic groups. The high-
est birth incidences for NTDs are reported amongst
descendants of the Celts in the UK, Canada and the USA.
These racial data suggest the importance of a genetic com-
ponent that has been borne out in family studies [7].
Family recurrence risks
Family studies suggest the recurrence risk for first-degree
relatives of affected individuals is approximately 1 in 30.
For second-degree relatives (the children of the mother's
sisters and brothers) the risk is approximately 1 in 220 [9].
However, the authors of the same study state there is not
yet agreement upon the accurate recurrence risk data for
family members. Others report a recurrence risk among
the mother's or an affected child's first-degree relatives is
as high as 1 in 70 to 140 [10,11]. McManus [12] reports
recurrence risks in first and second-degree relatives of 1 in
40 for sisters of the mother of an affected child, and 1 in
90 for the offspring of those sisters. She reported the
mother's brothers and the father's sisters and brothers to
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have lower recurrence risks of 1 in 140 to 1 in 190. Arata
et al [13] report that affected mothers appear to have only
a 0.5 to 1% chance of having a child with an NTD. This
last observation concurs with our finding that only one
mother with myelomeningocele has an affected child.
That child is one of 106 otherwise unaffected by an NTD.
Prenatal diagnosis and termination
The third aspect, prenatal diagnosis and termination of
affected pregnancies, is one that should be discussed with
all women in the reproductive age range and, more
importantly, with patients who have a family history of an
NTD. Folic acid taken orally on a daily basis is shown to
lower the occurrence and recurrence of NTDs in their own
offspring and in their relatives. The Medical Research
Council [14] was the first to prove conclusively that when
women who had had a previous child affected by an NTD
took 4.0 mg of folic acid daily, beginning three months
prior to conception, there was a 70% reduction in the
recurrence in subsequent offspring. Wald et al [15] have
recommended 5 mg daily. Because of the higher occur-
rence in first- and second-degree relatives, we recommend
4.0 mg daily, beginning three months prior to a planned
conception. We suggest the effect in the United States may
be nearer to a 40 – 50% reduction for two reasons. First,
Berry et al [16] demonstrated a 79% reduction in occur-
rence in north China (an area of high incidence) but only
40% in south China (where there is a low incidence)
when the women took 0.4 mg of folic acid periconceptu-
ally. The incidence of NTDs in the United States is closer
to that seen in south China rather than that in north
China. Secondly, recent data from Canada and Mexico are
the first to indicate that lower incidence communities on
the North American continent can achieve a 45 – 55%
reduction in occurrence with a regimen of 5 mg of folic
acid per week [17] and dietary fortification added to rec-
ommendations for supplementation periconceptually
with 0.4 mg dose of folic acid daily [8,18].
These data were obtained from the Birth Defects Clinic attendance records Figure 1
These data were obtained from the Birth Defects Clinic attendance records. Patients with myelomeningocele seen in this clinic 
represent 98% of individuals with myelomeningocele born in Washington State, USA, during the period that the state main-
tained a Birth Defects Registry. Preliminary data for the year 2003 suggest a decline in incidence to near the lowest level 
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Folic acid supplementation
When recent trends in the birth incidence of NTDs are
reported, they focus additionally on the effect that folic
acid has on the early second trimester prevalence of
affected fetuses. As for the epidemiological studies noted
above, these reports include varying types of cases; some
report only "spina bifida", others "spina bifida" and anen-
cephaly, and still others mention these two types and
encephalocele with or without hydrocephalus. Some
studies report only deaths due to complications in these
groups of patients as stillborns, or deaths in the neonatal
time period; other reports study all affected newborns,
and still others cover selective or spontaneously aborted
fetuses. Those that include time intervals after the intro-
duction of intrauterine diagnosis and selective termina-
tion do not take into consideration the variations in
incidence at different gestational ages and at birth,
whether stillborn or live [5]. Creasy and Alberman [2]
reported that 3% of 1216 (30 per 1000) spontaneously
aborted fetuses had central nervous system malforma-
tions. The majority of the malformations were NTDs.
Forty percent also had chromosomal aberrations. The
prevalence varied from about 21 per 1000 during each
three-week period of gestational age between 8 and 19
weeks, to 105 per 1000 amongst fetuses greater than 27
weeks gestational age. The live born birth incidence at that
time was 1.5 per 1000. Nishimura et al [4], reported 13
per 1000 spina bifida embryos amongst 3402 induced
abortion fetuses for social reasons at a gestational age
between 3 and 10 weeks old. The live born incidence at
the time was 2 per 1000. Adams et al [19] reported 10 of
34 fertilized ova up to the age of 17 days were malformed
(an incidence of 294 per 1000). Studies after the initiation
of prenatal diagnosis and before folic acid supplementa-
tion and fortification clearly demonstrate a remarkable
decrease in live born birth incidence ([1,20,21] and Figure
1). In Washington State, USA, prenatal diagnosis and ter-
mination of affected pregnancies began in 1980. Begin-
ning in 1991, concerned specialists and the media advised
supplementation with 400 mcg (0.4 mg) of folic acid
daily for women in the childbearing age group. Fortifica-
tion with an estimated 140 mcg (0.14 mg) per serving of
flour-containing foods was added to the recommenda-
tions, beginning in 1996, and implemented over the next
three years. The marked increase of 7 fold from 0.03 per
1000 in 2001 to 0.21 in 2002 coincided with the comple-
tion of fortification (Figure 1).
Conclusions
Our data and this review clearly demonstrate the effects of
intrauterine diagnosis and selective termination prior to
the recommendation for supplementation and fortifica-
tion of foodstuffs with folic acid. Because the reason for
termination of a pregnancy is not reportable in our state
and the USA, we cannot determine the effect of folic acid
on the prevalence of myelomeningocele and anencephaly
in first and early second trimester fetuses. Studies of the
effect of folic acid in reducing the birth incidence in com-
munities with a low incidence, and active prenatal diag-
nosis associated with termination of affected fetuses,
require longer-term studies than published to date. The
differences in data discussed above need to be considered
if one is to evaluate the effect of prenatal diagnosis and
elective termination as well as the effects of fortification or
supplementation with folic acid. We recommend that
these variables be discussed with women of reproductive
age, particularly if they are relatives of a patient with an
NTD. Regardless of the uncertainties, we recommend sup-
plementation of the diet of women, beginning three
months prior to an anticipated pregnancy. We recom-
mend all women of childbearing age take at least 400 mcg
of folic acid daily when they begin sexual activity. Rela-
tives of a patient with an NTD should take 4.0 mg daily,
beginning three months prior to conception.
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